Hiramoto Masaki

ヒラモトマサキ | Hiramoto Masaki

Affiliation and department：
Job title： Professor

Research field (3)： Tumor biology , Medical biochemistry , Molecular biology

Research keywords (8)： Cancer , Tyrosine kinase inhibitors , Autophagy , actin cytoskeleton , Invasion/metastasis , epithelial-mesenchymal transition , 2型糖尿病関連遺伝子 , 膵ベータ細胞

Research theme for competitive and other funds (7)：

2021 - 2024 EGFRチロシンキナーゼ阻害薬による上皮間葉転換誘導の分子機序解明と抑制法開発
2018 - 2021 Molecular mechanisms and pharmacological application of autophagy regulation by tyrosine kinase inhibitors
2017 - 2020 A novel therapeutic method for multiple myeloma by comprehensive control of intracellular protein degradation mechanism
2014 - 2017 ER-stress loading therapy in refractory multiple myeloma
2010 - 2012 Identification and functional analysis of the allele-specific DNA-binding factors that recognize type 2 diabetes susceptibility SNPs using nanobeads technology

Show all

Papers (74)：

Haruhide Udagawa, Nobuaki Funahashi, Wataru Nishimura, Takashi Uebanso, Miho Kawaguchi, Riku Asahi, Shigeru Nakajima, Takao Nammo, Masaki Hiramoto, Kazuki Yasuda. Glucocorticoid receptor-NECAB1 axis can negatively regulate insulin secretion in pancreatic β-cells. Scientific reports. 2023. 13. 1. 17958-17958
Naoharu Takano, Masaki Hiramoto, Yumiko Yamada, Hiroko Kokuba, Mayumi Tokuhisa, Hirotsugu Hino, Keisuke Miyazawa. Azithromycin, a potent autophagy inhibitor for cancer therapy, perturbs cytoskeletal protein dynamics. British Journal of Cancer. 2023. 128. 10. 1838-1849
Shota Moriya, Hiromi Kazama, Hirotsugu Hino, Naoharu Takano, Masaki Hiramoto, Shin Aizawa, Keisuke Miyazawa. Clarithromycin overcomes stromal cell-mediated drug resistance against proteasome inhibitors in myeloma cells via autophagy flux blockage leading to high NOXA expression. PloS one. 2023. 18. 12. e0295273
Keitaro Miyake, Naoharu Takano, Hiromi Kazama, Hiroyuki Kikuchi, Masaki Hiramoto, Kiyoaki Tsukahara, Keisuke Miyazawa. Ricolinostat enhances adavosertib-induced mitotic catastrophe in TP53-mutated head and neck squamous cell carcinoma cells. International journal of oncology. 2022. 60. 5. 54
Sumire Suzuki, Masato Ogawa, Masaya Miyazaki, Kohki Ota, Hiromi Kazama, Ayako Hirota, Naoharu Takano, Masaki Hiramoto, Keisuke Miyazawa. Lysosome-targeted drug combination induces multiple organelle dysfunctions and non-canonical death in pancreatic cancer cells. Oncology reports. 2022. 47. 2. 40

ｍore...

MISC (108)：

日野浩嗣, 田中良法, 竹谷浩介, 高野直治, 平本正樹, 相澤信, 宮澤啓介, 江藤真澄, 平井宗一. CDK4/6阻害薬abemaciclibが誘導する空胞の形成メカニズムの検討. 日本生化学会大会プログラム・講演要旨集. 2021. 94回. [P-493]
宇田川陽秀, 舟橋伸昭, 中野堅太, 柳田圭介, 岡村匡史, 添田光太郎, 南茂隆生, 平本正樹, 西村渉, 進藤英雄, et al. 内臓脂肪組織の脂肪細胞と中皮細胞における転写因子Gata5の機能解析. 糖尿病. 2021. 64. Suppl.1. 助成-2
宮崎誠也, 平本正樹, 風間宏美, 高野直治, 宮澤啓介. 分子標的薬Gefitinibの副次的標的分子GAKによるオートファジーフラックスの制御機構. 東京医科大学雑誌. 2021. 79. 1. 110-110
高野直治, 平本正樹, 風間宏美, 森谷昇太, 宮澤啓介. アジスロマイシンはDNA障害性抗がん剤によるリソソーム膜透過を亢進させ,殺細胞効果を増強する. 日本癌学会学術総会抄録集(Web). 2021. 80th
小川雅人, 鈴木菫, 平本正樹, 風間宏美, 高野直治, 宮澤啓介. Fingolimodとlapatinibとの併用は膵癌細胞株において複数の細胞小器官の機能障害を伴った細胞死を誘導する. 日本癌学会学術総会抄録集(Web). 2021. 80th

ｍore...

Education (4)：

- 1997 Tokyo Institute of Technology Bioscience and Biotechnology
- 1997 Tokyo Institute of Technology Graduate School, Division of Life Science and Engineering
- 1992 Tokyo Institute of Technology School of Engineering
- 1992 Tokyo Institute of Technology Faculty of Engineering

Professional career (1)：

博士(工学) (東京工業大学)

Work history (4)：

2013/09 - 現在 Tokyo Medical University
2009/01 - 2013/08 国立国際医療研究センター研究所
2005/07 - 2008/12 国立長寿医療センター研究所
1997/04 - 2005/06 日本大学医学部解剖学

Association Membership(s) (7)：

THE JAPANESE CANCER ASSOCIATION , THE JAPANESE BIOCHEMICAL SOCIETY , THE JAPAN SOCIETY OF HUMAN GENETICS , 日本糖尿病学会 , American Society for Cell Biology , 日本血液学会 , 日本分子生物学会

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page